Pfizer has posted a 98% decrease in net income attributable to common shareholders to $41m for the second quarter (Q2) of 2024, compared to $2.3bn in Q2 2023.
The pharmaceutical giant’s diluted earnings per share (EPS) also saw a sharp decline to $0.01 from $0.41 in the same quarter of the previous year.
Go deeper with GlobalData
The company’s revenues, however, saw a slight increase of 2%, amounting to $13.3bn, up from $13.0bn in Q2 2023.
This revenue growth is attributed to an operational increase of 3%, driven by the performance of acquired products, key in-line products and recent commercial launches.
These factors helped counterbalance the expected global decline in Comirnaty revenues and an unfavourable foreign exchange impact of $170m, or 1%.
When excluding the contributions from Comirnaty and Paxlovid, Pfizer’s revenues were $12.8bn, marking an operational increase of 14% or $1.6bn compared with the same quarter of the previous year.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataOperational revenue growth, excluding Comirnaty and Paxlovid, was primarily due to global revenues of $845m from Seagen, which Pfizer acquired in December 2023.
The growth was further supported by the Vyndaqel family, Eliquis and Nurtec ODT/Vydura globally, though partially offset by lower revenues from Xeljanz and Ibrance worldwide.
Pfizer has updated its full-year 2024 guidance, raising its adjusted diluted EPS forecast to between $2.45 and $2.65. The company also anticipates full-year 2024 revenues to be between $59.5bn and $62.5bn.
The updated revenue guidance includes an estimated $8.5bn from anticipated revenues for Comirnaty and Paxlovid, with approximately $5bn and $3.5bn expected respectively.
Pfizer chairman and CEO Dr Albert Bourla stated: “We are driving progress toward our 2024 strategic priorities through solid execution across the company. I am pleased with the strong performance of our product portfolio in the second quarter led by several of our acquired products, key in-line brands and recent commercial launches. Notably, we achieved exceptional growth in our oncology portfolio, with strong revenue contribution from our legacy-Seagen products.
“Overall, I am encouraged by our performance in the first half of 2024 and we remain focused on making a difference in the lives of patients as we continue to advance and strengthen our company.”
In May 2024, the company posted a reported net income of $3.11bn in Q1 2024 – a decrease of 44% from $5.54bn posted in Q1 2023.
